Near-Complete Response to Osimertinib for Advanced Non-Small-Cell Lung Cancer in a Pretreated Patient Bearing Rare Compound Exon 20 Mutation (S768I + V774M): A Case Report.

Third-generation tyrosine kinase inhibitors are the first-line gold standard in treating advanced non-small-cell lung cancer bearing common mutations, but data documenting clinical efficacy in uncommon mutations are currently limited. In this paper, we describe the case of a patient bearing uncommon compound mutations in exon 20, who experienced a near-complete response to third-line Osimertinib, with metabolic complete response of pulmonary, nodal and ostheolytic lesions. This radiological assessment corresponded to an ECOG PS improvement (from three to one) and a substantial clinical benefit for the patients.

Left Ventricular Lead Position Guided by Parametric Strain Echocardiography Improves Response to Cardiac Resynchronization Therapy.

Background: There is still a significant proportion of patients with heart failure who fail to improve after cardiac resynchronization therapy (CRT). The investigators used parametric two-dimensional speckle-tracking echocardiography with polar plots of the amplitude and timing of left ventricular (LV) longitudinal strain to guide implantation of the LV lead, with the aim of increasing CRT response.

Methods: Sixty-four patients who underwent LV lead implantation guided by two-dimensional speckle-tracking echocardiography (study group) and 64 patients treated with standard CRT implantation (control group) were retrospectively analyzed in this study.

Cardiac resynchronization therapy guided by multimodality cardiac imaging.

Aims: Up to 30-45% of implanted patients are non-responders to CRT. We evaluated the role of a 'CRT team' using cardiac magnetic resonance (CMR) and longitudinal myocardial strain to identify the target area defined as the most delayed and viable region for LV pacing.

Methods And Results: A total of 100 heart failure patients candidates for CRT divided into two groups were enrolled.